Biosimilar Cost in India: Price Gap vs Originator Biologics
How much biosimilars actually cost against originator biologics in India, with real trastuzumab, rituximab and insulin pricing examples and sources.
This covers documented biosimilar cost examples across oncology monoclonal antibodies and insulin, why the discount magnitude varies so much between molecules, and what that cost gap means for a hospital deciding what to stock and how to price it internally.
How much cheaper is a biosimilar than its originator biologic in India?
Biosimilar cost savings in India vary sharply by molecule rather than following one fixed percentage: Biocon's trastuzumab biosimilar Canmab reduced annual breast cancer treatment cost from an originator range of ₹15–20 lakh to under ₹5 lakh, according to industry pricing analyses, while Dr. Reddy's rituximab biosimilar Reditux, the world's first rituximab biosimilar when launched in 2007, was priced 30–40% below the originator.
This variance reflects differences in manufacturing complexity, competitive intensity within each molecule's biosimilar market, and how many biosimilar entrants exist for a given reference product. A molecule with several competing biosimilars typically shows a steeper cumulative price decline than one with only a single biosimilar entrant.
What does the trastuzumab biosimilar cost example show about oncology drug pricing?
Trastuzumab, used in HER2-positive breast cancer, illustrates the largest documented price gap in this drug category specifically because the originator biologic, Herceptin, was priced at a level that put a full year of treatment out of reach for most Indian patients without insurance.
Biocon's biosimilar brought that annual cost from ₹15–20 lakh down to under ₹5 lakh, and Intas has separately launched its own trastuzumab biosimilar in the Indian market at a comparable discount.
This scale of price reduction is why India's biosimilar approval pathway, described in our companion guide on biosimilars in India, has been positioned domestically as an access mechanism for high-cost oncology biologics specifically, more than for lower-cost biologic categories where the absolute rupee gap matters less to a patient's total treatment burden.
How does rituximab biosimilar pricing compare to trastuzumab's?
Rituximab biosimilar cost savings in India follow a smaller relative discount than trastuzumab's, with Dr. Reddy's Reditux launched around 30–40% below the originator price rather than the dramatic multiple seen with trastuzumab biosimilars. Reditux holds particular significance as the world's first rituximab biosimilar, approved in India in 2007 and subsequently sold across several developing-country markets.
Intas has also launched a rituximab biosimilar, Mabtas, in the Indian market, adding a second competing option within this molecule's biosimilar category. The presence of multiple rituximab biosimilar entrants is itself a factor that keeps downward pressure on price across the category, distinct from any single manufacturer's individual pricing decision.
Rituximab treats a different disease category than trastuzumab, spanning certain lymphomas and autoimmune indications, which means hospital demand volume and the resulting competitive dynamics between the two molecules aren't directly comparable even though both are oncology-adjacent biologics with a long biosimilar track record in India.
What does biosimilar cost look like for insulin specifically?
Insulin glargine biosimilar cost data from international markets, where more mature price-tracking exists, shows a median 21.6% price decrease across 28 European countries over the past decade following biosimilar entry, with 2022 median pricing at €9.0 for originator Lantus against €7.0 for the biosimilar Semglee. Biocon Biologics was the first Indian company to secure FDA approval for a biosimilar with Semglee, insulin glargine, in 2021.
Indian domestic insulin pricing operates under a separate NPPA price-control framework that applies to both originator and biosimilar insulin formulations, which is a distinct mechanism from the market-competition-driven price decline documented in the European insulin glargine data above. Our companion piece on insulin price and cost in India covers that NPPA ceiling-price structure in detail.
This distinction matters for formulary planning: a hospital pricing an insulin biosimilar against NPPA's ceiling faces a different cost calculus than one pricing a market-competitive oncology biosimilar like trastuzumab or rituximab against an uncontrolled originator price.
Why doesn't biosimilar cost follow one uniform discount rate across all molecules?
This price reduction depends on manufacturing complexity specific to each biologic, the number of competing biosimilar entrants for that molecule, and whether the category falls under direct price control versus open market competition. A single "biosimilars cost X% less" figure simply doesn't hold up molecule to molecule.
A biologic with a complex, hard-to-replicate manufacturing process supports fewer competing biosimilars and correspondingly smaller price declines than a simpler molecule with multiple manufacturers competing for market share.
A hospital or insurer evaluating biosimilar cost for formulary planning purposes needs molecule-specific pricing data rather than applying a general assumption from one well-publicised example like trastuzumab to a different biologic category entirely.
What does biosimilar cost mean for hospital pharmacy stocking decisions?
A hospital that can reliably stock the biosimilar option for a high-cost biologic converts what would otherwise be an unaffordable prescription into a treatment its own pharmacy can fulfil and track.
That's a continuity-of-care benefit distinct from the savings itself, since the patient's full treatment record stays inside the institution rather than fragmenting across an external high-cost drug supplier.
Medyzen's managed hospital pharmacy services are built around exactly this kind of reliable in-house stocking for drugs that would otherwise send a patient elsewhere, and our piece on prescription leakage covers what that outside referral costs a hospital in lost continuity and lost revenue over a full treatment course.
Sources
- 1Indian regulator approves first trastuzumab 'similar biologic' — GaBI Online, Generics and Biosimilars Initiative
- 2Intas launches trastuzumab similar biologic in India at 65% discount — GaBI Online
- 3Role of biosimilar introduction on insulin glargine prices: a retrospective analysis in 28 European countries — National Institutes of Health, National Library of Medicine
- 4Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19 — National Institutes of Health, National Library of Medicine
- 5Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
This article is for informational purposes and is not a substitute for professional medical or financial advice. Pricing figures are drawn from cited industry and peer-reviewed sources and vary by hospital, region and treatment course. Consult the treating clinician and hospital pharmacy for current pricing on any specific biosimilar.
FAQ
Frequently asked questions
Yes. Biocon's trastuzumab biosimilar Canmab has been documented to bring annual breast cancer treatment cost down from an originator range of ₹15–20 lakh to under ₹5 lakh, though individual patient costs vary by treatment duration, dose and hospital pricing.
The two molecules sit in different competitive and manufacturing contexts. Reditux launched around 30–40% below rituximab's originator price, a smaller relative gap than trastuzumab biosimilars show, reflecting differences in each molecule's specific market and production economics rather than a general rule about biosimilar discounts.
Biosimilar pricing in India is generally market-driven rather than directly price-controlled, except where a specific formulation, such as certain insulin products, falls under NPPA's scheduled formulation list and ceiling-price mechanism.
No. A biosimilar's lower price reflects reduced marketing spend and competitive market dynamics, not a lower regulatory quality bar. Every approved biosimilar in India clears the same CDSCO comparability requirements regardless of its price relative to the originator.
Available international data, including the European insulin glargine example, shows biosimilar and even originator pricing tends to decline further as more biosimilar competitors enter a given molecule's market, though this isn't guaranteed for every category and depends on how many manufacturers actually compete within it.
Dr. Rajesh IyerMBBS, MD (Pharmacology)
Clinical Pharmacologist
Dr. Rajesh Iyer is a clinical pharmacologist focusing on drug interactions, adverse-effect profiles, biosimilars, and drug-scheduling regulation in India.